Acute liver failure following immune checkpoint inhibitors - 06/10/23
, Clément Monet a, cAbstract |
We report the case of a 64-year-old man admitted to intensive care unit for liver failure secondary to immune-mediated hepatitis. This patient suffered from a progressing laryngeal squamous cell carcinoma. A treatment was started with immune checkpoint inhibitors combining anti PD-L1 plus novel anti-TIGIT or placebo (ATEZOLIZUMAB plus TIRAGOLUMAB or placebo), as part of a clinical trial. The patient then developed immune-mediated hepatitis, proven by liver biopsy. Despite 14 days of corticosteroids at 2 mg/kg the condition of the patient worsened, with the development of liver failure. The patient was admitted to intensive care unit, treated with plasma exchange, and made a complete recovery from this life-threatening condition. To our knowledge this is the case of a successful use of plasma exchange to treat ATEZOLIZUMAB +/- TIRAGOLUMAB induced liver toxicity.
Insights |
Plasma exchange could be a potential lifesaving treatment to severe immune-mediated hepatitis.
Le texte complet de cet article est disponible en PDF.Keywords : Acute liver failure, Immune check point inhibitors, Immunotherapy, Drug-induced, Liver injury, Plasma exchange
Vol 47 - N° 8
Article 102203- octobre 2023 Retour au numéro
Article précédent
- Combination immune checkpoint therapy carried on despite grade 4 immune-related hepatotoxicity during treatment of metastatic melanoma: Case report and review of literature
- Angèle Lallement, Anouck Lamoureux, Michael Hummelsberger, Alexandre Maria, Lucy Meunier
- Small bowel entrapment after OTSC deployment for endoscopic closure of a colonic iatrogenic perforation
- Renato Medas, Rui Morais, Margarida Marques, Carlos Soares, Guilherme Macedo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?